MedTrace Logo

The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients

NCT05419206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 167

Last updated 2022-06-15

No results posted yet for this study

Summary

The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation can be unnoticed in these patients.

Conditions

  • COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality

Interventions

DIAGNOSTIC_TEST

CMV DNA analysis

CMV DNA quantitative viral load levels were studied

Sponsors & Collaborators

  • Ramazan Gozukucuk

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-15
Primary Completion
2021-12-31
Completion
2022-05-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05419206 on ClinicalTrials.gov